eyenovia
host
investor
call
discuss
recent
licensing
agreements
resulting
total
potential
license
payments
development
cost
reimbursement
savings
approximately
million
nasdaq
company
reaffirms
near
term
milestones
microstat
nda
microline
presbyopia
program
phase
iii
results
call
scheduled
today
tuesday
october
et
new
york
globe
newswire
eyenovia
nasdaq
eyen
clinical
stage
ophthalmic
biopharmaceutical
company
developing
pipeline
microdose
array
print
therapeutics
today
announced
management
host
investor
conference
call
discuss
company
recent
licensing
agreements
provide
update
company
short
term
milestones
drug
programs
call
scheduled
today
october
et
october
eyenovia
bausch
health
companies
nyse
tsx
bhc
announced
affiliate
bausch
health
acquired
exclusive
license
united
states
canada
development
commercialization
micropine
investigational
microdose
formulation
atropine
ophthalmic
solution
investigated
reduction
pediatric
myopia
progression
also
known
nearsightedness
children
ages
investigational
formulation
atropine
delivered
eyenovia
proprietary
dispenser
technology
terms
licensing
agreement
bausch
health
eyenovia
eligible
receive
million
license
payments
million
due
upfront
balance
due
upon
milestones
upon
signing
bausch
health
also
assumed
oversight
costs
related
ongoing
phase
chaperone
clinical
trial
upfront
license
payment
reduced
operating
expenses
expected
yield
cash
flow
eyenovia
approximately
million
total
end
commercialization
eyenovia
eligible
receive
royalties
ranging
digit
percentages
gross
profit
sales
united
states
canada
william
blair
company
served
eyenovia
exclusive
financial
advisor
transaction
august
eyenovia
arctic
vision
hong
kong
limited
announced
arctic
vision
acquired
exclusive
license
greater
china
south
korea
development
commercialization
micropine
microline
investigational
microdose
formulation
pilocarpine
treatment
presbyopia
delivered
optejet
dispenser
technology
terms
arctic
vision
agreement
eyenovia
may
receive
total
approximately
million
upfront
payments
well
additional
payments
based
various
development
regulatory
milestones
including
initiation
clinical
research
approvals
greater
china
south
korea
development
costs
addition
arctic
vision
purchase
supply
micropine
microline
eyenovia
products
supplied
eyenovia
pay
eyenovia
digit
percentage
royalty
net
sales
products
subject
certain
adjustments
eyenovia
pay
digit
percentage
payments
royalties
net
proceeds
supply
asian
licensee
pursuant
arrangement
eyenovia
reacquired
rights
products
greater
china
south
korea
original
licensee
sean
ianchulev
chief
executive
officer
chief
medical
officer
eyenovia
stated
pleased
reached
agreements
bausch
health
arctic
vision
expect
upfront
license
payments
potential
cost
savings
recent
business
development
activities
could
provide
us
sufficient
capital
beginning
within
timeframe
plan
advance
product
candidates
including
mydcombi
microstat
mydriasis
remain
track
submit
new
drug
application
end
year
microline
presbyopia
plan
complete
two
phase
clinical
trials
subject
impacts
together
estimate
two
indications
could
represent
market
opportunity
excess
approximately
billion
united
states
alone
additionally
believe
licensing
agreements
validate
use
optejet
technology
platform
additional
ophthalmic
conditions
longer
term
could
provide
us
significant
upside
particularly
micropine
approved
united
states
china
look
forward
providing
context
around
business
development
activities
afternoon
conference
call
ianchulev
concluded
conference
call
webcast
details
tuesday
october
et
pt
domestic
international
webcast
link
http
eyenovia
eyenovia
nasdaq
eyen
clinical
stage
ophthalmic
biopharmaceutical
company
developing
pipeline
microdose
array
print
therapeutics
eyenovia
pipeline
currently
focused
development
programs
presbyopia
myopia
progression
mydriasis
information
please
visit
statements
except
historical
information
statements
expectations
assumptions
contained
press
release
statements
statements
include
limited
statements
express
intentions
beliefs
expectations
strategies
predictions
statements
relating
future
activities
future
events
conditions
including
estimated
market
opportunities
product
candidates
potential
revenue
licensing
transactions
statements
based
current
expectations
estimates
projections
business
based
part
assumptions
made
management
statements
guarantees
future
performance
involve
risks
uncertainties
assumptions
difficult
predict
therefore
actual
outcomes
results
may
likely
differ
materially
expressed
forecasted
statements
due
numerous
factors
discussed
time
time
documents
file
sec
addition
statements
could
affected
risks
uncertainties
related
among
things
estimates
regarding
potential
market
opportunity
product
candidates
potential
revenue
licensing
transactions
reliance
third
parties
develop
commercialize
product
candidates
impacts
uncertainty
related
ability
us
partners
timely
develop
implement
maintain
manufacturing
commercialization
marketing
capabilities
strategies
product
candidates
risks
clinical
trials
including
limited
costs
design
initiation
enrollment
could
still
adversely
impacted
resulting
social
distancing
timing
progress
results
trials
timing
ability
submit
applications
obtain
maintain
regulatory
approvals
product
candidates
potential
impacts
supply
chain
potential
advantages
product
candidates
rate
degree
market
acceptance
clinical
utility
product
candidates
fluctuations
financial
results
particularly
given
market
conditions
potential
economic
impact
need
raise
additional
capital
intellectual
property
risks
ability
attract
retain
key
personnel
changes
legal
regulatory
legislative
environments
markets
operate
impact
changes
ability
obtain
regulatory
approval
products
competitive
position
statements
speak
date
made
except
may
required
applicable
securities
laws
eyenovia
undertake
obligation
update
statements
eyenovia
investor
contacts
john
gandolfo
jgandolfo
eric
ribner
lifesci
advisors
llc
eric
eyenovia
media
contact
